Indications:Treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children above 6 years of age with atomoxetine. Treatment of adolescents/17-17 years of age with atomoxetine in the treatment of ADHD in adults and children over the age of 17. Treatment of adult ADHD in adults with a diagnosis of ADHD by collection of data from the Adult ADHD Diagnostic and Statistical Manual, text Revision. ADHD treatment includes assessments of the severity of symptoms and of treatment efficacy. ADHD treatment may be stopped in the morning and continued in the evening and is indicated in a dose-dependent manner in children and adolescents aged 13-17 years of age.Dosage and Administration:The recommended daily dose of atomoxetine for adults is 5 mg, which should be taken at the same time every day. The usual dose for adults is 20 mg, while the dose for children is 5 mg daily.
The recommended daily dosage for adults is 5 mg, taken at the same time every day. The usual dosage for children is 1 mg, taken once per day. The recommended daily dosage of atomoxetine for children is 2.5 mg, taken once per day. The recommended daily dosage of atomoxetine for adolescents is 5 mg daily. The recommended daily dosage of atomoxetine for adolescents is 2.5 mg daily. The recommended daily dosage of atomoxetine for children is 5 mg daily.
Atomoxetine is a selective serotonin reuptake inhibitor (SSRI) for the treatment of attention-deficit/hyperactivity disorder (ADHD). It also has the effect of increasing the amount of dopamine available in the brain. It has the disadvantage that it can cause sleepiness and drowsiness. The medicine has the advantage that it can be used by children for the treatment of ADHD.
Atomoxetine is available as a capsule and in the form of an injection in the dose-dependent manner. The recommended daily dose for adults is 5 mg. The recommended dose of atomoxetine for children is 2.5 mg daily. The dose is adjusted accordingly according to the child's age and weight and the severity of the symptoms. The dosage may be increased to 5 mg daily by a doctor.
The use of atomoxetine in patients with hypersensitivity to atomoxetine or any other component of the product is contraindicated. It is also contraindicated in patients with severe hepatic impairment, severe renal impairment, or patients taking antiepileptic drugs. Patients with a history of drug hypersensitivity to any ingredient in the product should not use atomoxetine. Patients with a history of drug hypersensitivity to other substances in the product should avoid using atomoxetine. Patients with a history of hypersensitivity to alcohol should not use atomoxetine. Patients with the following conditions should not use atomoxetine: abrupt onset of symptoms (e.g., blurred vision or sensitivity to light and alcohol), or history of drug or alcohol abuse. Patients with epilepsy, a history of drug hypersensitivity, epilepsy-related seizures, or epilepsy should avoid using atomoxetine. Patients with cardiac disorders, heart failure, or heart attack should avoid using atomoxetine. Patients with a history of drug hypersensitivity to nitrates or MAO-inhibitors should avoid using atomoxetine. Patients with a history of drug- or alcohol-induced liver damage should avoid using atomoxetine. Patients with a history of drug or alcohol-induced heart rhythm disturbances should avoid using atomoxetine. Patients with a history of drug-induced central nervous system depression should avoid using atomoxetine. Patients with an abnormality of the metabolism of atomoxetine should avoid using atomoxetine. Patients with a history of drug-induced seizures should avoid using atomoxetine. Patients with a history of drug-related serious allergic reactions should not use atomoxetine. Patients with a history of drug- or alcohol-related serious allergic reactions should avoid using atomoxetine.
The following table outlines the prices of brand-name and generic versions of Strattera US and Eli Lilly’s Strattera. The prices are not adjusted for inflation. Generic drugs are priced elsewhere under the same pricing model, which requires an inflation factor of 2.5 to 3.0 depending upon the brand and generic prices.
| Brand name | Generic |
| Lilly | |
| Price (USD) | $0.00 (generic) |
| Generic name | Strattera |
Atomoxetine is a selective norepinephrine reuptake inhibitor. It belongs to the group of drugs known as 5-alpha-reductase inhibitors.
This drug is used to treat narcolepsy and attention-deficit/hyperactivity disorder (ADHD). It works by slowing down the production of certain chemicals in the brain that can help improve attention, focus, and impulse control. Atomoxetine is also used to treat ADHD symptoms.
Atomoxetine was originally developed to treat patients with ADHD. The active ingredient was atomoxetine, which was approved by the FDA in 2003. In 2018, the drug was approved to treat ADHD and narcolepsy.
The prices for this drug are not adjusted for inflation.
Atomoxetine is a brand name.
Lilly is a registered trademark of Pfizer.
Strattera is a registered trademark of Eli Lilly and Company.
Lilly’s price is not adjusted for inflation.
Atomoxetine is a prescription drug. It is used to treat:
Atomoxetine is also used to treat:
Generic is available in generic form at a much lower price than the brand name version. The price per tablet is 10.25 for generic and 30.25 for brand name.
Atomoxetine is taken orally and can be given with or without food.
The usual starting dose is 15 mg, but depending on the severity of symptoms and individual response to treatment, it may be increased to 40 mg or decreased to 25 mg. The dosage can be increased to 60 mg once daily. The maximum daily dose is 5 mg per day.
Strattera, commonly known by its generic name atomoxetine, is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). It was the first medication approved for the treatment of this condition.
The global market for ADHD stimulant medications is significant and growing. As of 2024, the global ADHD stimulant medications market size was estimated at USD 3.67 billion. The market is expected to grow at a compound annual growth rate of 4.5% from around 2023 to 2033, reaching nearly USD 3.11 billion by 2033[3].
The global ADHD stimulant medications market was valued at USD 3.67 billion in 2024 and is expected to compound at a
29% cost-effectiveness gain at 5 novel drug name combinations per million prescriptions served[5].
The pricing of pricing considerations depends on which ADHOTTENSIC Tramway pricing plan is selected and approved. Regardless of which plan is used, the ADHD stimulant medications market price should be competitively priced. Even if the 5 novel drug name combination plan is chosen as the best approach to budget-conscious consumers, there should be room for improvement and/or erosion in market growth[3][4].
On the-�side expense, the ADHD stimulant medication market size isn’t likely to grow at aarkable price tag. The cost- margin should be adequate and consistent. However, there is an opportunity for incremental growth, with up to 35% in some regions[5].
The global ADHD stimulant medication market is based on the pricing structure of the industry:
Gaps and economies of two to four months a year exist in countries like United Kingdom, Italy, and Germany for late-stage businesses:
Strattera, a leading medication in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), is the first drug approved for the treatment of this condition. This medication is a non-stimulant that increases the levels of norepinephrine and dopamine in the brain. This article explores the recent pricing estimate for Strattera (atomoxetine), including out-of-pocket costs, fakes, coupon codes, and extended-release (X-R) formulations of this medication[3]. By considering factors such as pricing strategies, how the drug price varies from drug to drug, potential out-of-pocket costs, extended-release (X-R) cost, and insights into market share and revenue, the full value of the Strattera value chain, and access to savings programs, this non-stimulant medication is a valuable tool in the treatment of ADHD[3].
The global ADHD stimulant medication market was valued at USD 3.67 billion in 2024 and is expected to increase at a value at which it is estimated to reach USD 4.8 billion next year. The market is expected to grow at a compound annual growth rate of 4.
Medically reviewed by Jessica Swirble, PharmDLast updated on April 18, 2025
Drug Information| | |
Strattera is a medication used to treat attention-deficit hyperactivity disorder (ADHD). It works by increasing the levels of norepinephrine in the brain.
Note:The active ingredient in Strattera is atomoxetine. Approval time for this is late 2017. Narcosemitriptants are often prescribed for ADHD, but these drugs are only approved for treatment of ADHD. The active ingredient in atomoxetine is atomoxetine.
Atomoxetine is an atypical antipsychotic medication. It works by helping to restore the balance of certain natural substances in the brain. This can help treat ADHD and help improve emotional regulation, self-esteem, and overall quality of life in individuals with ADHD.
The effects of Strattera can vary from person to person. It is usually taken once or twice a day, depending on the doctor's directions. Common side effects include drowsiness, dizziness, and irritability. These effects are more likely with higher doses.
Strattera is available in several forms, including:
The dose and duration of treatment with Strattera can vary from person to person. The inhaler is the most common option, followed by powder inhalation. Inhaler side effects may include drowsiness, dizziness, and fatigue.
The dose and duration of treatment with atomoxetine can also vary depending on the doctor's instructions. The tablet is usually started at a low dose and increased as needed. The capsule is usually started at a higher dose and increased as needed. The pill is usually started at a low dose and increased as needed.
Patients should be aware of the potential side effects of atomoxetine when taking Strattera. These can include dry mouth, constipation, and weight gain.
Strattera is not recommended for use in children. The drug's effects can be permanent, and the medication should not be used by children or adolescents under 18 years of age.
The safety and efficacy of Strattera in children and adolescents with ADHD has not been established. Strattera must be used only under a doctor's supervision. It is not recommended for use in adolescents younger than 18 years of age.
Strattera is not approved for use in adults. It is not approved for use in pediatric patients.
Strattera is not approved for use in treating women. It is not indicated in treating men with ADHD.
Strattera should not be taken by patients who are pregnant or breastfeeding. It can pose risks to the fetus and infant.
Strattera is not approved for use in pediatric patients.
Strattera is not approved for use in treating adults with ADHD.
Patients should be aware of the potential side effects of Strattera when taking Strattera when taking their medication, especially if they have high blood pressure, have low blood levels of norepinephrine, or if they have experienced allergic reactions to atomoxetine or other drugs taken by mouth. These effects can be permanent and the drug may be used by young people for other uses.
Strattera is not approved for use in treating children under the age of 18 years with ADHD. It is not recommended for use by children under the age of 10 years.
It can potentially harm a developing fetus or may even make Strattera more effective in treating a child's existing symptoms.
Strattera should not be used in patients with narrow-angle glaucoma or a history of adrenal gland problems.
Stade de France Pharmacy